Not enough data
Eva Wesley's articles predominantly focus on the healthcare and pharmaceutical industry, with an emphasis on business transactions and investment activities. Her coverage is heavily reliant on press releases and private sector announcements, indicating a preference for official sources of information.
Given her focus on business transactions within the healthcare industry, Eva may be most receptive to pitches that involve exclusive insights into company strategies, market trends, or expert analysis from reputable figures in the field of healthcare finance or corporate strategy.
Since Eva does not specify a geographic focus but focuses primarily on international companies involved in healthcare investments and transactions, pitches should aim to provide global perspectives rather than being limited to specific regions.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Eva Wesley
Galicia has approved its Biotechnology Strategy 2026–2030, mobilizing €805 million to boost competitiveness. The plan prioritizes health, agri-food, and advanced technologies, including the 1HealthAI hub. It emphasizes biomedical innovation, precision medicine, and data integration. New funding calls and a business accelerator will support R&D, collaboration, and growth across the regional biotechnology ecosystem.
Gilead's upcoming development plan for Assembly Biosciences' HSV drugs could reshape the herpes market. ABI-5366 and ABI-1179 have shown strong antiviral results and may form a new treatment class reducing outbreaks and transmission. If confirmed, HSV could shift from symptomatic care to prevention, significantly boosting Gilead's virology strategy and valuation.
Eli Lilly stock hit a record high, surpassing $1 trillion market value after strong product demand. Shares surged over 7%, entering price discovery with bullish RSI and MACD signals. Elliott Wave analysis shows a powerful long-term uptrend, though overbought conditions suggest possible short-term pullbacks. Overall momentum remains positive if support levels hold in coming sessions.
Biotechnology company Graph Therapeutics raised 5 million dollars in a funding round led by Daphni, with support from existing investors. Including grants from Austrian agencies, total funding exceeds 10 million. The company develops an AI platform using patient cell data to discover drug targets, expand its pipeline, and pursue partnerships and licensing for precision therapies.
By: Eva Wesley
Karyopharm Therapeutics is a US biotechnology company focused on developing innovative cancer and serious disease therapies. Its value depends heavily on clinical trial success, regulatory approvals, and its drug pipeline. Like many biotech firms, it prioritizes long-term research over profits, making it a high-risk, growth-oriented investment influenced by scientific and regulatory outcomes.
By: Eva Wesley
A blood test detecting tumor DNA may personalize treatment for colorectal cancer patients with liver metastases after surgery. The GALAXY study shows patients with detectable DNA benefit from adjuvant chemotherapy, while negative patients have outcomes without it. The biomarker helps identify residual disease, predict relapse risk, and avoid unnecessary chemotherapy, though routine use requires evidence.
Facing declining biotech financing and competitiveness, the European Commission has proposed the Biotech Act to boost investment, streamline regulation, and expand production. With Europe lagging behind the US and China in trials and funding, plan mobilizes up to €10 billion, accelerates clinical procedures, and aims to attract private capital while retaining innovation within the EU.
Biovalley Investments Partner (BIP) sold its entire stake in BIC Incubatori FVG to Innova, both Trieste-based firms and longtime users of the incubator. BIP will continue collaborating with Innova on investments. The deal lets BIP refocus on core biotech, hydrogen transport, and AI-driven medical technologies, including its ChemoMaker oncology robot, while Innova advances BIC's growth.
By: Eva Wesley
A CSIC-UMH study identifies heightened interferon signaling as a key factor in women's greater Alzheimer's vulnerability. Analysis of human brain tissue and animal models showed stronger immune activation, increased inflammation, and cognitive decline in females. Blocking this pathway reduced damage and improved memory, suggesting interferon modulation as a promising therapeutic strategy, pending future clinical validation.
Emily.AI, Quirónsalud's explainable AI medical device, became a global finalist at the AI for Good Summit 2026 after competing with 500+ projects. Developed in Catalonia, it personalizes oxygen therapy in real time, improving outcomes across care settings. With remote monitoring and automation, it enhances efficiency, supports SDGs, and reduces clinical workload while optimizing oxygen use.
